Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $54.4 million.

  • Zevra Therapeutics' Cash & Equivalents rose 74.02% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year increase of 74.02%. This contributed to the annual value of $33.8 million for FY2024, which is 2151.97% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Cash & Equivalents is $54.4 million, which was up 74.02% from $47.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Cash & Equivalents registered a high of $132.3 million during Q2 2021, and its lowest value of $33.8 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $66.7 million, with a median of $54.4 million in 2025.
  • Per our database at Business Quant, Zevra Therapeutics' Cash & Equivalents skyrocketed by 312228.35% in 2021 and then crashed by 5991.6% in 2023.
  • Zevra Therapeutics' Cash & Equivalents (Quarter) stood at $112.3 million in 2021, then crashed by 41.73% to $65.5 million in 2022, then tumbled by 34.24% to $43.0 million in 2023, then decreased by 21.52% to $33.8 million in 2024, then soared by 61.13% to $54.4 million in 2025.
  • Its Cash & Equivalents stands at $54.4 million for Q3 2025, versus $47.7 million for Q2 2025 and $37.3 million for Q1 2025.